Global PD-1 and PD-L1 Inhibitors Market

Report ID : 1115 | Published : 2021-07-26 | Pages: 140 | Format:

PD-1 and PD-L1 Inhibitors are playing a pivotal role in cancer management treatment. PD-1 and PD-L1 Inhibitors therapy is a specialized and targeted treatment that acts via blocking the activity of PD-1 and PD-L1 immune checkpoint proteins from the surface of cells. PD-1 and PD-L1 Inhibitors have accounted for proven effectiveness and satisfactory results in the treatment of cancer. Increasing cases for cancer patients across the globe and rising focus on specific & effective cancer management treatments are propelling the demand for oncology drugs and boosting the market for global PD-1 and PD-L1 Inhibitors market. Increasing emphasis on effective cancer treatment and rising economic burden due to cancer treatment procedures has led pharmaceutical manufacturers to invest significantly in research and development activities to fulfill the existing and latent demand for oncology drugs.

The Global PD-1 and PD-L1 Inhibitors market size is valued at US$ 22,076.9 Million, and it is expected to reach US$ XX Million in 2030, recording a promising CAGR of 15.6% during the period of 2019-2030. By region, in 2019, North America dominates the market with a share of XX % of the global PD-1 and PD-L1 Inhibitors market. US is the key market, holding the majority of the market for PD-1 and PD-L1 Inhibitors in the region.

The Global PD-1 and PD-L1 Inhibitors market is categorized on the basis of drug type, disease type, and region. On the basis of drug type, the market is segmented into Atezolizumab, Avelumab, Cemiplimab, Durvalumab, Nivolumab, Pembrolizumab, Sintilimab, and Others (Pipeline). On the basis of Indication Type, the market is segmented into Colorectal Cancer, Hodgkins Lymphoma, Melanoma, Merkel Cell Carcinoma, Non-Small-Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma, Urothelial Bladder Cancer, and Others.  Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among all, North America is expected to dominate the market during the analysis of forecast period.

The key players of this market include Merck Co., Bristol-Myers Squibb, Roche, AstraZeneca, Pfizer, Jiangsu HengRui Medicine, Regeneron Pharmaceuticals, ONO PHARMACEUTICAL CO., LTD., Eli Lilly and Company, Innovent Biologics, Inc., BeiGene, Junshi Biosciences Co., Biocad, 4D pharma plc., Agenus Inc., Calithera., Curis, Inc., Constellation Pharmaceuticals, Inc., Compass Therapeutics, Corvus Pharmaceuticals, CytomX Therapeutics, Inc., eFFECTOR Therapeutics, Inc., Jounce Therapeutics, Inc., MacroGenics, Inc., Mirati Therapeutics, Inc.  , Moderna, Inc., MultiVir, Inc., NovoCure Ltd., NeoImmuneTech, Inc., Syndax Pharmaceuticals, PrimeVax Immuno-Oncology Inc., Incyte Corporation, Trillium Therapeutics Inc., and other prominent players.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global PD-1 and PD-L1 Inhibitors Market Snapshot

Chapter 4. Global PD-1 and PD-L1 Inhibitors Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Penetration & Growth Prospect Mapping

4.6. Clinical Trial/Pipeline Analysis

4.7. Industry Analysis – Porter’s Five Forces Analysis

4.8. Competitive Landscape & Market Share Analysis

4.9. Key Trends in the Market

Chapter 5. Market Segmentation 1: Drugs Estimates & Trend Analysis

5.1. Drugs Type & Market Share, 2019 & 2028

5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2018 to 2028 for the following Drugs:

5.2.1. Pembrolizumab

5.2.2. Nivolumab

5.2.3. Atezolizumab

5.2.4. Durvalumab

5.2.5. Avelumab

5.2.6. Cemiplimab

5.2.7. Sintilimab

5.2.8. Others

Chapter 6. PD-1 and PD-L1 Inhibitors Market Segmentation 2: Indication Estimates & Trend Analysis

6.1. Indication Analysis & Market Share, 2019 & 2028

6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2019 to 2028 for the following Indication:

6.2.1. Melanoma

6.2.2. NSCLC

6.2.3. Renal cell carcinoma

6.2.4. Urothelial bladder cancer

6.2.5. Hodgkins Lymphoma

6.2.6. Merkel cell carcinoma

6.2.7. Colorectal cancer

6.2.8. Others

Chapter 7. PD-1 and PD-L1 Inhibitors Market Segmentation 3: Regional Estimates & Trend Analysis

7.1. North America

7.1.1. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) estimates and forecasts by Drugs, 2019-2028

7.1.2. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) estimates and forecasts by Indication, 2019-2028

7.1.3. North America PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) estimates and forecasts by Country, 2019-2028

7.1.3.1. U.S.

7.1.3.2. Canada

7.2. Europe

7.2.1. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) by Drugs, 2019-2028

7.2.2. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) by Indication, 2019-2028

7.2.3. Europe PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) by Country, 2019-2028

7.2.3.1. Germany

7.2.3.2. Poland

7.2.3.3. France

7.2.3.4. Italy

7.2.3.5. Spain

7.2.3.6. UK

7.2.3.7. Rest of Europe

7.3. Asia Pacific

7.3.1. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) by Drugs, 2019-2028

7.3.2. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) by Indication, 2019-2028

7.3.3. Asia Pacific PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) by Country, 2019-2028

7.3.3.1. China

7.3.3.2. India

7.3.3.3. Japan

7.3.3.4. Australia

7.3.3.5. Rest of Asia Pacific

7.4. Latin America

7.4.1. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) by Drugs, (US$ Million)

7.4.2. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) by Indication, (US$ Million)

7.4.3. Latin America PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) by Country, (US$ Million) 2019-2028

7.4.3.1. Brazil

7.4.3.2. Rest of Latin America

7.5. MEA

7.5.1. MEA revenue PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) by Drug, (US$ Million) 2019-2028

7.5.2. MEA revenue PD-1 and PD-L1 Inhibitors Market revenue (US$ Million) by country, (US$ Million) 2019-2028

7.5.2.1. South Africa

7.5.2.2. Rest of MEA

Chapter 8. Competitive Landscape

8.1. Major M &A /Research Institutes Partnerships, Alliances, and Agreements

8.2. Funding Activities

8.3. Company Profiles

8.3.1. Merck Co.

8.3.2. Bristol-Myers Squibb

8.3.3. Roche

8.3.4. AstraZeneca

8.3.5. Pfizer

8.3.6. Jiangsu HengRui Medicine

8.3.7. Regeneron Pharmaceuticals

8.3.8. ONO PHARMACEUTICAL CO., LTD.

8.3.9. Eli Lilly and Company

8.3.10. Innovent Biologics, Inc.

8.3.11. BeiGene

8.3.12. Junshi Biosciences Co.

8.3.13. Biocad

8.3.14. 4D pharma plc.

8.3.15. Agenus Inc.

8.3.16. Calithera.

8.3.17. Curis, Inc.

8.3.18. Constellation Pharmaceuticals, Inc.

8.3.19. Compass Therapeutics

8.3.20. Corvus Pharmaceuticals

8.3.21. CytomX Therapeutics, Inc.

8.3.22. eFFECTOR Therapeutics, Inc.

8.3.23. Jounce Therapeutics, Inc.

8.3.24. MacroGenics, Inc.

8.3.25. Mirati Therapeutics, Inc. 

8.3.26. Moderna, Inc.

8.3.27. MultiVir, Inc.

8.3.28. NovoCure Ltd.

8.3.29. NeoImmuneTech, Inc.

8.3.30. Syndax Pharmaceuticals

8.3.31. PrimeVax Immuno-Oncology Inc.

8.3.32. Incyte Corporation

8.3.33. Trillium Therapeutics Inc.

Global PD-1 and PD-L1 Inhibitors Market Segmentation:

Global PD-1 and PD-L1 Inhibitors Market Based on Drug type

  • Atezolizumab
  • Avelumab
  • Cemiplimab
  • Durvalumab
  • Nivolumab
  • Pembrolizumab
  • Sintilimab
  • Others (Pipeline)

Global PD-1 and PD-L1 Inhibitors Market Based on Disease Type

  • Colorectal Cancer
  • Hodgkins Lymphoma
  • Melanoma
  • Merkel Cell Carcinoma
  • Non-Small-Cell Lung Carcinoma (NSCLC)
  • Renal Cell Carcinoma
  • Urothelial Bladder Cancer
  • Others

Global PD-1 and PD-L1 Inhibitors Market Based on Region

Europe PD-1 and PD-L1 Inhibitors Market by Country

  • U.K.
  • Germany
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe

North America PD-1 and PD-L1 Inhibitors Market by Country

  • U.S.
  • Canada

Asia Pacific PD-1 and PD-L1 Inhibitors Market by Country

  • India
  • China
  • Japan
  • South Korea
  • Australia & New Zealand

Latin America PD-1 and PD-L1 Inhibitors Market by Country

  • Brazil
  • Mexico
  • Rest of Latin America

Middle East & Africa PD-1 and PD-L1 Inhibitors Market by Country

  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients